Impact of KELIM chemosensitivity and interval cytoreduction on survival outcomes from neoadjuvant weekly dose-dense paclitaxel +/- bevacizumab : pooled analysis of ICON8 and ICON8B phase III trials.

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Benoit You, Olivier Colomban, Domenico Radice, Aleksandra Gentry-Maharaj, Francesco Schiavone, Pauline Corbaux, Gilles Freyer, Iain McNeish, Jonathan A. Ledermann, A. Clamp
DOI: 10.1016/j.ijgc.2025.102892
Cited by: 1

Fields of Study & Subjects

Lung Cancer Research Studies Cancer Treatment and Pharmacology Pancreatic and Hepatic Oncology Research

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
2
Pages
102892–102892
Publication date
1 February 2026
Language
EN